Anchored in work undertaken at University of Minnesota in perfusion decellularization and recellularization, Miromatrix Medical is structured around raising the bar in regenerative medicine by introducing the next generation of extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. With the focus on making progress towards whole-organ solutions - effectively eliminating the organ transplant wait list by bringing the promise of fully biological organs to the people that need it - the firm's development pipeline includes many organ-derived medical devices to meet healthcare needs. Strategically partnering with The Mayo Clinic, The Texas Heart Institute and with Mount Sinai Hospital, Miromatrix Medical advances its organ programs, Miromatrix Medical is currently engaged in the development of various whole organs with the liver program furthest in development followed closely by the kidney program.
